Redx Pharma begins testing lead drug in phase II trial for idiopathic pulmonary fibrosis - Lisa Anson Chief Executive Officer, Redx Pharma 00:00:00
Appointed in 2018, Lisa Anson has led the transformation of Redx into a clinical stage biotech with two programmes in clinical development and a growing pipeline of preclinical assets. During this time the company also secured major partnership deals for five assets with large and speciality pharma and secured long term financing with new blue chip life science focused investors.
